Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026
Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026
Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026
Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026
Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026
Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026
Company Medical Device

Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation

Fineline Cube Jun 22, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a...

Company Drug

Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment

Fineline Cube Jun 22, 2022

Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...

Company Drug

CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies

Fineline Cube Jun 22, 2022

The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...

Company Medical Device

Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China

Fineline Cube Jun 22, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...

Policy / Regulatory R&D

Beijing Introduces White List System for Biomedical R&D Item Imports

Fineline Cube Jun 21, 2022

Beijing has announced the introduction of a ‘white list’ system to facilitate the import of...

Company Drug

Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China

Fineline Cube Jun 21, 2022

China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA)...

Company

AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base

Fineline Cube Jun 21, 2022

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...

Company Drug

CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance

Fineline Cube Jun 21, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...

Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Company Drug

Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma

Fineline Cube Jun 20, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...

Policy / Regulatory

China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules

Fineline Cube Jun 20, 2022

China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...

Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Posts pagination

1 … 612 613 614 … 618

Recent updates

  • Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
  • PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
  • Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
  • Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
  • ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.